Studies reveal that in PD1/PDL1 therapy-resistant patients, tumor-associated macrophages (TAMs) impede antitumor immunity and foster resistance to PD1/PDL1 therapy [1, 2]. The gene discussed is PDCD1; the disease is neoplasm.